"Repair Of Ovarian Damage And Dampening Of Inflammatory Microenvironment By Administration Of Monocytic-Granulocytic Progenitors With Immune Modulatory Activities" in Patent Application Approval Process (USPTO 20240002792).

A patent application by Creative Medical Technologies Inc. discusses the potential use of stem cells to treat ovarian failure. The application proposes a method that involves combining myeloid lineage cells with mesenchymal stem cells and administering the resulting microvesicles to the patient. The application suggests that this approach could be an effective treatment for ovarian failure, but further research is needed. The method aims to repair ovarian damage and reduce inflammation in the ovarian microenvironment. [Extracted from the article]